BRIEF—Advanz signs deal with GP Pharm for a peptide specialty injectable generic for European countries

Privately-held UK headquartered Advanz Pharma has signed an exclusive licensing and supply agreement with GP Pharm for a peptide specialty injectable generic in a rare disease indication for multiple European countries.

GP Pharm is a leading vertically integrated organization specializing in complex peptide developments.

This partnership is another confirmatory step in Advanz’s strategy to be a partner of choice for the commercialization of specialty, hospital, and rare disease medicines in Europe.

Advanz’s product portfolio and pipeline comprises innovative medicines, specialty generics and biosimilars, and originator brands.

Its products cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines.